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Abstract
Background
Low-dose aspirin has been shown to reduce the incidence of cancer, but its role in the treat-
ment of cancer is uncertain.
Objectives
We conducted a systematic search of the scientific literature on aspirin taken by patients fol-
lowing a diagnosis of cancer, together with appropriate meta-analyses.
Methods
Searches were completed in Medline and Embase in December 2015 using a pre-defined
search strategy. References and abstracts of all the selected papers were scanned and
expert colleagues were contacted for additional studies. Two reviewers applied pre-deter-
mined eligibility criteria (cross-sectional, cohort and controlled studies, and aspirin taken
after a diagnosis of cancer), assessed study quality and extracted data on cancer cause-
specific deaths, overall mortality and incidence of metastases. Random effects meta-analy-
ses and planned sub-group analyses were completed separately for observational and
experimental studies. Heterogeneity and publication bias were assessed in sensitivity anal-
yses and appropriate omissions made. Papers were examined for any reference to bleeding
and authors of the papers were contacted and questioned.
Results
Five reports of randomised trials were identified, together with forty two observational stud-
ies: sixteen on colorectal cancer, ten on breast and ten on prostate cancer mortality. Pooling
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of eleven observational reports of the effect of aspirin on cause-specific mortality from colon
cancer, after the omission of one report identified on the basis of sensitivity analyses, gave
a hazard ratio (HR) of 0.76 (95% CI 0.66, 0.88) with reduced heterogeneity (P = 0.04). The
cause specific mortality in five reports of patients with breast cancer showed significant het-
erogeneity (P<0.0005) but the omission of one outlying study reduced heterogeneity (P =
0.19) and led to an HR = 0.87 (95% CI 0.69, 1.09). Heterogeneity between nine studies of
prostate cancer was significant, but again, the omission of one study led to acceptable
homogeneity (P = 0.26) and an overall HR = 0.89 (95% CI 0.79–0.99). Six single studies of
other cancers suggested reductions in cause specific mortality by aspirin, and in five the
effect is statistically significant. There were no significant differences between the pooled
HRs for the three main cancers and after the omission of three reports already identified in
sensitivity analyses heterogeneity was removed and revealed an overall HR of 0.83 (95%
CI 0.76–0.90). A mutation of PIK3CA was present in about 20% of patients, and appeared
to explain most of the reduction in colon cancer mortality by aspirin. Data were not adequate
to examine the importance of this or any other marker in the effect of aspirin in the other can-
cers. On bleeding attributable to aspirin two reports stated that there had been no side effect
or bleeding attributable to aspirin. Authors on the other reports were written to and 21 replied
stating that no data on bleeding were available.
Conclusions and Implications
The study highlights the need for randomised trials of aspirin treatment in a variety of can-
cers. While these are awaited there is an urgent need for evidence from observational stud-
ies of aspirin and the less common cancers, and for more evidence of the relevance of
possible bio-markers of the aspirin effect on a wide variety of cancers. In the meantime it is
urged that patients in whom a cancer is diagnosed should be given details of this research,
together with its limitations, to enable each to make an informed decision as to whether or
not to take low-dose aspirin.
Systematic Review Protocol Number
CRD42015014145
Introduction
Despite significant advances in diagnosis and treatment in recent decades, cancer is still one of
the main causes of morbidity and mortality worldwide. It claims more than 81,000 males and
74,000 females every year in the UK alone, the crude annual mortality rate being about 250
deaths in every 100,000 people [1]. Much effort is now being focused on ‘targeted cancer thera-
pies’, that is, drugs that interfere with specific molecules involved in cancer cell growth and cell
survival, but as yet there have been few successes.
There is convincing evidence that regular low-dose aspirin not only reduces vascular disease
incidence and mortality [2,3], but also reduces the incidence and mortality of colorectal and
other cancers [4–7]. Furthermore, there is growing evidence which suggests that aspirin, used
as an adjuvant treatment following a diagnosis of cancer, may reduce metastatic spread and
may increase the survival of patients with cancer.
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Chan et al (2009) [8], Langley (2011) [9,10] and others have pointed out that effects of aspi-
rin on certain biological mechanisms justify an expectation of benefit from aspirin used as an
adjunct treatment of patients with cancer. These effects include an interruption of tumour
growth, a retardation of metastatic spread, an inhibition of angiogenesis, enhancements of
both DNA mismatch repair and cellular apoptosis and an abrogation of invasiveness. Benefit
from treatment with aspirin is therefore not unexpected.
Our aim in what follows is to provide a comprehensive systematic review and meta-analysis
of the available evidence on the effects of aspirin used as an adjunct treatment of cancer in the
reduction of mortality and metastatic spread.
Methods
The review protocol was registered in PROSPERO (registration number CRD42015014145). In
reporting we have followed the PRISMA guidelines [11].
In December 2015 observational and interventional studies in Medline and Embase were
searched using a pre-defined strategy with indexed descriptors and keywords including “aspi-
rin”, “acetylsalicylic acid”, “cancer” “tumour”, “neoplasm”, “mortality”, “death”, “adverse
effect”, “bleed”. The search was limited to human studies in peer-reviewed journals and confer-
ence abstracts. Reference lists of the included studies were also searched and recent conference
proceedings scanned and topic experts contacted for additional studies.
Studies were selected for inclusion in meta-analyses if (a) the studied population comprised
patients diagnosed with cancer; (b) aspirin was taken regularly after cancer diagnosis indepen-
dently of whether it had been taken before diagnosis; (c) they were case-control studies, cohort
studies or controlled trials; and (d) cause-specific mortality was available. All-cause cancer
mortality, incidence of metastases and adverse effects were noted but were not criteria for
selection.
Two reviewers independently excluded reports that did not meet inclusion criteria based on
title and abstract. Full published reports were obtained for the remainder, and inclusion criteria
were applied.
The origin of the patient group and other details in each report were examined, and if there
appeared to be two reports based on the same patients, if the evidence required for the meta-
analyses was not clear, or if important items were missing, the author(s) was contacted and
asked for clarification. Authors of all the papers were also asked whether they had data on gas-
trointestinal or other bleeding, and if this had been a concern at any time. All these processes
were conducted by one of the authors and were checked as appropriate by another author.
The methodological quality of the included studies was assessed and graded independently
by two authors using the Newcastle-Ottawa Scale [12]. Differences in grading of reports on a
nine point scale, were discussed and agreed.
Meta-analyses were conducted grouping the studies according to study design: intervention
and observational studies. Subgroup analyses were conducted according to cancer types, key
mutations and whether or not patients had taken aspirin only after diagnosis.
The summary statistics derived in the meta-analyses were either a hazard ratio or a risk
ratio each with 95% confidence intervals. The analyses were carried out using the statistical
package STATA. The inverse-variance method was used to weight the individual studies and
provide the pooled estimate of effects. A 'random effects' model was used throughout to incor-
porate an estimate of between-study variation into the calculation of common effects. Funnel
plots were created to highlight outlying studies and look at publication bias. Publication bias
was assessed using Egger's test [13]. Sensitivity analyses were performed to assess the influence
of individual studies on the combined hazard ratios. Heterogeneity was assessed using the Q
Aspirin in the Treatment of Cancer
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statistic and investigated by repeating the meta-analyses excluding, first low scoring studies
and then, if substantial heterogeneity was still present, outlying studies, identified by the sensi-
tivity analyses were omitted.
Results
The literature search identified 373 reports and following omissions of duplicates and irrele-
vant reports, 42 were found to be relevant and gave sufficient data to be included in meta-anal-
yses. We present a summary diagram in Fig 1 showing the selection process.
Table 1 summarises a few basic features of the papers included in the meta-analyses together
with those upon which further investigations are based. A final column gives an assessment of
quality of the studies, judged according to the Newcastle-Ottawa Scale [12].
In the tables that follow we summarise the individual papers and report the results of meta-
analyses and when available we give data for both cause-specific mortality and all-cause
mortality.
Aspirin, specific and overall mortality
Our search identified four reports of randomised trials, together with a report of pooled trials
[14] (Table 2). The ad hoc trials [15–18] were small and the results did not achieve significance.
The report by Rothwell et al (2012) [14] describes a 6.5 year follow-up of five early vascular tri-
als, during which time 987 new cancers developed. In these, aspirin was associated with a
reduction in cancer deaths (HR 0.71; 95% confidence limits (CI) 0.57, 0.90). The effect of aspi-
rin in all five trials together is homogeneous (P = 0.30), but this result should be taken with cau-
tion as clinical heterogeneity such as differences between the design of the studies, the patient
populations etc. may be too great to justify the pooling of results.
In Table 3 data from observational studies are listed within three main groups: 16 on colo-
rectal cancer [8,19–32], 10 on breast [34–43] and ten on prostate cancers [44–53], and then
data relating to six other cancers [54–59]. A column contains comments of possible relevance
on some of the reports of possible relevance.
The sixteen reports of patients with colorectal cancer [8,19–33] give a pooled hazard ratio
(HR) of 0.71 (95% CI 0.58, 0.87) for cause specific mortality (11 reports) and there is marked
heterogeneity. Sensitivity analyses identified Bains [20] and when omitted there is reduced het-
erogeneity, and the HR is 0.76 (95% CI 0.66, 0.88). Three of these studies give data for the effect
of aspirin in the proximal and the distal colon separately. Two of them [21,22] are homoge-
neous and combining them gives: HR 0.74 (95% CI 0.52, 1.04) for proximal colon and HR 1.03
(95% CI 0.78, 1.35) for distal colon. The third study [26] shows that compared with the effect
in the distal colon, aspirin was associated with an HR of 0.84 (95% CI 0.56, 1.24) for cancer in
the proximal colon. Pooled data for all-cause mortality are shown in the Table.
Data for ten breast cancer studies [34–43] are shown in Table 3, and a pooled HR on the
effect of aspirin on cause-specific deaths cancer mortality in five studies is 0.69 (95% CI 0.46,
1.02). There is significant heterogeneity (P<0.0005), but on omitting a paper identified in sen-
sitivity analysis [38] the heterogeneity is reduced (P = 0.19) and the HR becomes (0.87; 95% CI
0.69, 1.09). Data on all-cause mortality is given in the Table.
Amongst ten studies of aspirin and prostate cancer [44–53] nine give a cause specific mor-
tality of 0.94 (95% CI 0.76, 1.17) with significant heterogeneity, Sensitivity analyses indicated
that one study is responsible [44] and its omission led to an HR of 0.89 (95% CI 0.79, 0.99) and
heterogeneity p = 0.26.
Six studies of other cancers [54–59] are included in Table 3. Benefit from aspirin is sug-
gested in all six, but they are too diverse to justify meta-analysis.
Aspirin in the Treatment of Cancer
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A few of the reports give details of grade or stage of the cancer, but these were too few to
enable any relevant analyses in relation to the effect of aspirin. Later however we quote a few
comments on aspirin and ‘advanced’ cancer. Figs 2 and 3 respectively show the Forest plots of
the cause specific mortality and the all-cause mortality (although only two reports [44,52]
stated all-cause mortality in patients with prostate cancer).
It is possible to examine the pooling of the HRs for the three main cancers, and it seems not
unreasonable to do this because the various pairs of HRs do not differ significantly (thus: for
Fig 1. Prisma flow diagram.
doi:10.1371/journal.pone.0152402.g001
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Table 1. Details of the studies.
Authors Source Design Number of aspirin
users and non-
users. Duration of
follow-up
Deaths in aspirin users and
all-cause deaths
Comment Grade
Randomised controlled trials
Rothwell et al.
[14]
Five early vascular
trials
Randomised for
vascular reduction
17,285 subjects
randomised
385 deaths on aspirin, 402
deaths on placebo
RCT
Lipton et al.
[15]
Series of patients Ad hoc randomisation 57 patients
randomised, F-U 24
months
Life table analysis, Numbers
N.A.
RCT
LeBeau et al.
[16]
Series of patients Ad hoc randomisation 303 patients
randomised, F-U 18
months
152 deaths on aspirin, 147
deaths on placebo
RCT
Cregan et al.
[17]
Series of patients Ad-hoc randomisation
of patients with renal
cancer
176 patients
randomised, F-U 8.8
months
52 total deaths on aspirin, 56
deaths on placebo
RCT
Liu et al. [18] Sequence of patients Randomised by
admission to ward
445 users, 1153
non-users, F-U 5
years
217 deaths in users, 685
deaths in non-users
RCT
Reports of colorectal cancer
Bastiaannet
et al. [19]
Eindhoven Cancer
Registry
Cohort of 4481 patients
with cancer
3305 users, 1176
non-users, F-U N.A.
114 CRC deaths in users,
610 deaths in non-users
Most appear to have
had aspirin, not other
NSAIDs
9
Bains et al
[20]
Cancer Registry of
Norway
Cohort of 25644
patients with cancer
6109 users, Non
users N.A.
1172 CRC deaths in users,
6356 CRC deaths in non-
users, 2088 total deaths in
users, 7595 total deaths in
non-users
Conference
presentation
7
Cardwell et al.
[21]
UK Clinical Practice
Research Datalink
Nested case-control in
a cohort of 4794
patients with cancer
Numbers N.A. Mean
F-U 7.2 years
395 CRC deaths in users,
1164 deaths in non-users,
700 total deaths in users,
1514 total deaths in non-
users
9
Chan et al. [8] US Nurses and
Health Professionals
Cohorts
Cohort of patients with
cancer
549 users, 730 non-
users. Median F-U
11.8 years
81 CRC deaths in users, 141
CRC deaths in non-users,
193 total deaths in users, 287
total deaths in non-users
Varied dose of
aspirin judged by
frequency
8
Coghill et al.
[22]
Seattle Cancer
Family Register
Cohort of patients with
cancer
234 users, 293 non-
users. Mean F-U 8
years
37 events in users, 72 events
in non-users
9
Din et al [23] Series of cases of
cancer
Case-control selected
patients from a trial
cohort
354 users, 526 non-
users. F-U 1 years
125 deaths in users, 761 in
non-users
NSAIDS, but data for
aspirin given
6
Domingo
et al. [24]
Series of patients Cohort study 125 users, 771 non-
users. F-U N.A.
22 deaths in users, 174 in
non-users
Incidence and all-
cause mortality in
relation to PIK3CA
state
8
Fuchs et al.
[25]
Series of patients Cohort study 72 users, 830 users.
Mean F-U 2.4 years
Numbers of deaths N.A. 5
Goh et al. [26] Series of patients Cohort study 92 users, 634 non-
users. F-U ‘long
term’
21 CRC deaths in users, 160
CRC deaths in non-users
9
Liao et al. [27] Nurses HS and
Health Professionals
Cohorts
Selected cohort of
patients
337 users, 627 non-
users. Mean F-U 5
years
68 CRC deaths in users, 122
CRC deaths in non-users
7
(Continued)
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Table 1. (Continued)
Authors Source Design Number of aspirin
users and non-
users. Duration of
follow-up
Deaths in aspirin users and
all-cause deaths
Comment Grade
McCowan
et al. [28]
Database of
residents
Cohort of selected new
patients
1340 users, 1650
non-users, F-U 11
years
420 CRC deaths in users,
601 CRC deaths in non-
users, 897 total deaths in
users, 1101 total deaths in
non-users
9
Ng et al. [29] Series of patients Cohort study 75 users, 725 non-
users. F-U 5 years
19 CRC recurrence in users,
21, CRC recurrence in non-
users., 14 total deaths in
users, 146 total deaths in
non-users
7
Reimers et al
[30]
Cohort of study of
cancer patients
178 users, 784 non-
users. F-U N.A.
68 deaths in users, 380
deaths in non-users
HLA class 1 antigen
groups amalgamated
9
Sun et al. [31] US Nurses and
Health Professionals
cohorts
cohort of selected
cancer patients
931 subjects. Other
details N.A. F-U 28
years
931 incident cases. Detailed
numbers N.A.
3
Walker et al.
[32]
UK GP Research
Database
Cohort of selected
patients
476 users, 10141
non-users. Median
F-U 1.7 years
192 total deaths in users,
3910 total deaths in non-
users
9
Zanders et al
[33]
Eindhoven Cancer
Registry
Cohort of selected
patients with diabetes
490 users, 156 non-
users. F-U 1.5 years
Numbers N.A. Diabetic patients 9
Reports of breast cancer
Barron et al
[34]
Ireland National
Cancer Registry
Cohort of 12507
patients with cancer
764users, 4540 non-
users. F-U 7.4 years
50 breast cancer deaths in
users, 311 breast cancer
deaths in non-users, 311
total deaths in users, 459
total deaths in non-users
7
Blair et al [35] Iowa Women’s
Health Study
Cohort of 591 women
with cancer
472 users, 120 non-
users, F-U 15 years
26 breast cancer deaths in
users, 22 breast cancer
deaths in non-users, 57 total
deaths in users, 44 total
deaths in non-users
8
Bowers et al
[36]
A Centre for Cancer
Care
Cohort of 440 women
with cancer
159 users, 281 non-
users. F-U N.A.
Number of deaths not
available
NSAIDs. 81% were
aspirin
7
Cronon-
Fenton [37]
Population based
cohort in Denmark
Cohort study of 34188
patients
Median F-U 7.1
years
Numbers N.A. Conference report 6
Frazer et al.
[38]
Database of
residents
Cohort of 4627 women 1244 users, 3383
non-users. F-U 16
years
252 breast cancer deaths in
users, 563 breast cancer
deaths in non-users, 577
total cancer deaths in users,
1225 total cancer in non-
users
8
Holmes et al.
[39]
US Nurses Health
Study
Cohort of 4164 women Number of users N.
A. 5521 non-users.
F-U n.a.
109 breast cancer deaths in
users, 56 breast cancer
deaths in non-users
8
Holmes et al.
[40]
National Cancer
Registry
Nested case-control
within 27426 women
1661 users, 3322
non-users. F-U up to
5 years
395 breast cancer deaths in
users, 750 breast cancer
deaths in non-users
9
Kwan et al.
[41]
Cohort of cancer
patients
Cohort of 2292 women Total 2292 women.
Mean F-U 2.5 years
41 recurrent cancers in
users, 209 recurrent cancers
in non-users
NSAIDs 8
Murray et al.
[42]
UK Clinical Practice
Research Datalink
Nested case-control
study
1173 users, 1173
non-users. Mean
F-U 6.9 years
262/1435 cancer deaths in
users, 1056/5697 cancer
deaths in non-users
9
(Continued)
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Table 1. (Continued)
Authors Source Design Number of aspirin
users and non-
users. Duration of
follow-up
Deaths in aspirin users and
all-cause deaths
Comment Grade
Wernli et al.
[43]
Cohort of cancer
survivors
Cohort of 3058 selected
patients with breast
cancer
541 users of
NSAIDs, 2517 non-
users of NSAIDs.
F-U 6 years approx.
7 breast cancer deaths in
users, 141 breast cancer
deaths in non-users, 37 total
deaths in users, 383 total
deaths in non-users
NSAIDs 7
Reports of prostate cancer
Assayaq et al
[44]
UK National Cancer
Data Repository
Cohort of 11779 newly
diagnosed patients
Numbers in users N.
A. F-U 5.4 years
801 cancer deaths in users,
992 cancer deaths in non-
users, 1816 total deaths in
users, 1686 deaths in non-
users
9
Caon et al.
[45]
Patient series Cohort of newly 3851
diagnosed patients
509 users, 2428
non-users, F-U 7
years
194 cancer deaths in users,
904 cancer deaths in non-
users
8
Choe et al.
[46]
Patient registry Cohort of 5955 patients 1817 users, 1736 no
relevant drugs.
Medium F-U 70
months
36 cancer deaths in users,
298 cancer ca deaths in non-
users
7
Daugherty
et al. [47]
Screened cohort Cohort of patients with
cancer
Numbers N.A.
Medium F-U 5 years
136 cancer deaths 8
Dhillon et al.
[48]
US Health
Professionals cohort
Cohort study 1579 users, 1926
non-users, F-U up to
18 years
177 cancer deaths. Details N.
A.
8
Flahavan [49] Irish National Cancer
Registry
Cohort study of 2936 1131 users, 1805
non-users. Median
F-U 5.5 years
Numbers of deaths N.A. 8
Grytli et al.
[50]
Cancer Registry of
Norway
Cohort of selected
patients
1279 users, 3515
non-users. Mean
F-U 39 months
504 cancer deaths in users 9
Jacobs, Chun
et al. [51]
Series of patients Cohort study 45 users, 29 non-
users. Mean F-U
56.6 months
6 cancer deaths in users, 8
cancer deaths in non-users
6
Jacobs,
Newton et al.
[52]
Prospective cohort of
subjects
New cancer patients.
Also ‘High-risk’ patients
3600 users, 3058
non-users, F-U up to
9 years
134 cancer deaths in users,
112 cancer deaths in non-
users
8
Stock et al.
[53]
Cancer Registry cohort of selected
cancer patients
419 users, 1200
non-users. Maximum
F-U 120 months
115 cancer deaths in users,
338 cancer deaths in non-
users
NSAIDs 9
Reports of other cancers
Nagle et al
[54]
Series of women with
ovarian cancer
Cohort study of 1305
women with ovarian
cancer
Numbers N.A., F-U
4.9 years
834 deaths 6
Fontaine et al.
[55]
Series of patients
with lung cancer
Cohort study of women
with lung cancer
412 users, 1353
non-users, F-U 7.5
years
Numbers of deaths N.A. 7
Pastore et al.
[56]
Series of patients
with bladder cancer
Cohort of 574 patients
with bladder cancer
98 users, 56 non
users F-U 2 years
Numbers of deaths N.A. 8
Chae et al.
[57]
536 patients with
mixed cancers
Cohort of 536 women
with mixed cancers
54 users, 482 non-
users. Median F-U
8.8 months
Numbers of deaths N.A. 4
(Continued)
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colon and breast cancer P = 0.90; for colon and prostate cancer P = 0.06 and for breast and
prostate cancers P = 0.18). An overall meta-analysis for cause-specific mortality from these
three cancers is 0.78 (95% CI 0.66, 0.92). Naturally, this has to be accepted with great caution,
Table 1. (Continued)
Authors Source Design Number of aspirin
users and non-
users. Duration of
follow-up
Deaths in aspirin users and
all-cause deaths
Comment Grade
Chae et al
[58]
Patients with
relapsed/refractory
chronic lymphocytic
leukaemia
Retrospective study of
280 patients with
chronic lymphocytic
leukaemia
37 users, 17 non-
users. Median F-U 4
years
Numbers of deaths N.A. 5
MacFarlane
et al [59]
Series of 2392
patients with head
and neck and
oesophageal cancers
Cohort study of 2392
patients with
oesophagus cancer;
1195 with head & neck
cancer
1197 oesophagus,
F-U 9 months, 1195
head & neck, F-U 35
months
965 oesophagus cancer
deaths, 509 head & neck
deaths cancer. Details N.A.
7
Reports included in other tables
Algra &
Rothwell [4]
Based on a literature
search
Overviews of 6 RCTs;
150 case-control
studies, and 45 cohort
studies
In case-control
studies. Followed for
up to 20 years
245 in RCTs; 141,577 in
case-control studies, 41,575
in cohort studies
Details on metastatic
spread in RCTs and
in 5 observational
studies
9
Ljung et al.
[60]
National Cancer
Registry
Selected patient cohort 3424users, 23104
non-users, F-U 5
years
Numbers with lymph node
metastases. Numbers N.A.
8
Kothari et al.
[61]
Two cancer centres Series of selected 999
patients with colon
cancer
49 users, 136 non-
users. Mean F-U 54
months
Detail of deaths N.A. 7
CI: conﬁdence interval; CRC: Colorectal cancer;; F-U: Follow-up; N.A.: not available; NSAID: non-steroidal anti-inﬂammatory drug; RCT: randomised
controlled trial; RR: risk ratio.
doi:10.1371/journal.pone.0152402.t001
Table 2. Mortality in randomized trial patients with cancer who took aspirin versus placebo/no-aspirin.
Study Design Cancer Aspirin/
none
Outcome Numbers of outcome events
aspirin/placebo
Effect of aspirin
(95% CI)
Rothwell Wilson
[14]
Pooled analysis of
ﬁve RCTs
All solid
cancers
385.402 Cancer deaths 385,402 HR 0.71 (0.57,0.90)
All deaths N.A. HR 0.81 (0.65, 1.00)
Lipton [15] RCT Colorectal 35,22 Cause-speciﬁc
mortality
N.A. HR 0.65 (0.02–18.06) a
Lebeau [16] RCT Lung 153/150 Cause-speciﬁc
mortality
152,147 HR 1.01 (0.81–1.27) a
Cregan [17] RCT Renal 89/87 Cause-speciﬁc
mortality
56,57 HR 0.91 (0.63–1.31) a
Liu et al [18] RCT b Oesophagus 445/658 Cause-speciﬁc
mortality
217,388 HR 0.83 (0.68, 1.01)
Cause speciﬁc mortality: HR 0.85 (0.74–0.97) heterogeneity p = 0.30
All-cause mortality: HR 0.81 (0.65–1.00) Rothwell et al [14] alone
CI: conﬁdence interval; HR Hazard Ratio; HR: hazard ratio; RCT: randomised controlled trial.
aHazard ratios taken from Langley [20]
bRandomisation was achieved by admitting patients to two different wards in which aspirin and placebo were given.
doi:10.1371/journal.pone.0152402.t002
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Table 3. Results of aspirin treatment of cancer in observational studies.
Study Aspirin/none Mortality Deaths
(aspirin, no
aspirin)
Results
(95% CI)
Comment
Colorectal cancer
Bastiaannet
et al [19]
275/ 1176 All-cause 114, 610 HR 0.77
(0.63, 0.95)
Frequent use HR 0.70 (0.57, 0.88)
Bains et al [20] 6109/19535 Speciﬁc 1172, 6356 HR 0.53
(0.50, 0.57)
All-cause 2088, 7595 HR 0.71
(0.68, 0.75)
Cardwell et al
[21]
1005/ 2365 Speciﬁc 395, 1164 HR 0.99
(0.86, 1.15)
Chan et al [8] 549/1279 Speciﬁc mort 81, 141 HR 0.71
(0.53, 0.95)
Speciﬁc: Only post diagnosis: RR 0.53 (0.33, 0.86). Pre
and post: RR 0.89 (0.59, 1.35)
All-cause 193, 287 HR 0.79
(0.65, 0.97)
All-cause: Only post diagnosis RR 0.68 (0.61, 0.92). Pre
and post RR 0.95 (0.71, 1.28)
Coghill et al [22] 56/346 Cause speciﬁc 37, 72 HR 0.76
(0.61, 0.95)
Din et al [23] 354/526 Cause speciﬁc 125, 761 OR 0.78
(0.65, 0.92)
Aspirin result; also data on NSAIDs a
Domingo et al
[24]
125/761 Recurrence 22, 174 HR 0.86
(0.55–1.35)
Wild and mutated combined
All-cause HR 0.88
(0.53, 1.47)
Fuchs et al [25] 72/830 Recurrence or
death
N.A. HR 0.48
(0.24, 0.99)
Compared with non-consistent use. Consistent users: HR
0.45 (0.21, 0.97) for disease recurrence
All-cause HR 0.52
(0.19, 1.46)
Goh et al [26] 92/726 Speciﬁc 21, 160 HR 0.71
(0.43, 1.16)
Death or recurrence 0.38 (0.17, 0.84). Beneﬁt only after 5
years)
Liao et al [27] 155/395 Speciﬁc 68, 122 HR 0.83
(0.61–1.23)
Wild and mutated combined
403/964 All-cause HR 0.87
(0.71, 1.06)
McCowan et al
[28]
894/2980 Speciﬁc 420, 601 HR 0.58
(0.45, 0.75)
All-cause 897, 1101 HR 0.67
(0.57, 0.79)
Ng et al [29] 75/724 Recurrence or
death
19, 214 HR0.68
(0.42, 1.11)
Consistent aspirin HR 0.51 (0.28, 0.95)
Overall
mortality
14, 146 HR 0.63
(0.35, 1.12)
Reimers et al
[30]
178/784 Overall
mortality
68, 380 RR 0.67
(0.52, 0.88) c
HLA class 1 antigen groups amalgamated
Sun et al [31] ?/931 Cancer speciﬁc
survival
931 total
events
HR 0.77
(0.52, 1.14)
CTNNBI mutated and non- mutated groups combined
Walker et al [32] 2619/13,994 All-cause 192, 3910 HR 0.91
(0.82, 1.00)
No aspirin pre diagnosis: HR 0.99 (0.84, 1.16); aspirin pre
diagnosis: HR 0.86 (0.76, 0.98)
Zanders et al
[33]
490/ All-cause N.A. HR 0.98
(0.93, 1.03)
Diabetic patients
Colorectal speciﬁc mortality: HR 0.71 (0.58, 0.87) heterogeneity p = 0.0005
With Bains omitted b: HR 0.76 (0.66, 0.88) heterogeneity p = 0.035
All-cause mortality: HR 0.80 (0.70, 0.92) heterogeneity p = 0.0005; no omission removes signiﬁcant heterogeneity
Breast cancer
(Continued)
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Table 3. (Continued)
Study Aspirin/none Mortality Deaths
(aspirin, no
aspirin)
Results
(95% CI)
Comment
Barron et al [34] 764/4540 Speciﬁc 50, 311 HR 0.98
(0.74, 1.30)
Selected de-novo aspirin users
Total 311,495 HR 1.11
(0.83, 1.50)
Blair et al [35] 254/591 Speciﬁc 26, 22 HR 0.53
(0.30,-0.93)
Selected overweight women
All-cause 57, 44 HR 0.53
(0.36–0.79)
Bowers et al
[36]
159/440 Recurrence N.A. OR 0.48
(0.22, 0.98)
NSAIDs, 81% of which are stated to be aspirin a
Cronin-Fenton
et al [37]
Recurrence N.A. HR 1.0
(0.90, 1.1)
Conference report
Frazer et al [38] 815/1802 Speciﬁc 252, 563 HR 0.42
(0.31–0.55)
All-cause 577, 1225 HR 0.53
(0.45–0.63)
Holmes et al.
[39]
?4164/11416 person/
years
Speciﬁc 109, 56 RR 0.36
(0.24–0.54)
All-cause RR 0.54
(0.41–0.70)
Holmes et al
[40]
1661 cases 3322
controls
Speciﬁc 395, 750 HR 0.96
(0.80, 1.16)
Kwan et al [41] 270/2292 Recurrence 41, 209 RR 1.09
(0.74, 1.61)
Murray et al [42] 262/1435 Speciﬁc 262, 1435 OR 1.00
(0.71, 1.41)
‘High’ dose aspirin 0.94 (0.48, 1.84), but dose imprecise
Wernli et al [43] 7 breast cancer
deaths
Speciﬁc 7, 141 HR 0.64
(0.27, 1.37)
37 total deaths All-cause 37, 383 HR 0.91
(0.65, 1.29)
Breast speciﬁc mortality: HR 0.69 (0.46, 1.02), heterogeneity p<0.0005
With Frazer omitted b: HR 0.87 (0.69, 1.09), heterogeneity p = 0.186
All-cause mortality: HR 0.73 (0.49, 1.08), heterogeneity p<0.0005; no omission removes signiﬁcant heterogeneity
Prostate cancer
Assayag et al
[44]
801/1793 Speciﬁc 801, 992 1.46 (1.29,
1.65)
Aspirin only after diagnosis: HR 1.84 (1.59, 2.12) cause
speciﬁc; HR 1.70 (1.53, 1.88) all-cause. Aspirin also
before diagnosis: HR 0.97 (0.81. 1.16) cause speciﬁc; HR
0.98 (0.87, 1.18) all-cause
1686/3502 All-cause 1816, 1686 1.37 (1.26,
1.50)
Caon et al [45] 917/3851 Cause speciﬁc 194, 904 HR 0.91
(0.65, 1.28)
Choe et al [46] 1817/5552 Cause-speciﬁc 36, 298 HR 0.43
(0.21–0.87)
Daugherty et al
[47]
136 Cause speciﬁc 136 total HR 0.77
(0.48, 1.25)
Advanced disease: HR 0.37 (0.15, 0.92). Localised
disease: HR 0.86 (0.47, 1.58)
Dhillon et al [48] N.A. Cause speciﬁc 177 total HR 1.08
(0.76–1.54)
Flahavan et al
[49]
1131/2936 Cause-speciﬁc N.A. HR 0.88
(0.67, 1.15)
High aspirin: HR 0.73 (0.51, 1.05)
(Continued)
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particularly as there is significant heterogeneity (P<0.0005), even though the omission of the
three papers already identified as ‘outliers’ by sensitivity analysis [20,38,40] reduces the hetero-
geneity (P = 0.03) and gives an overall HR of 0.83 (95% CI 0.76, 0.90). Egger’s test for publica-
tion bias [13] is not significant (P = 0.30).
Aspirin and metastatic spread
An effect of aspirin on metastatic spread is clearly an evidence of treatment and the data in
Table 4, although sparse, are therefore of considerable importance. Two studies of breast can-
cer [14,46], two of prostate [23,38] and one of both cancers together with colon [4], give evi-
dence of a reduction in spread by aspirin. A combined estimate gives a relative risk for aspirin
of 0.77 (95% CI 0.65, 0.92), though there is significant heterogeneity between the studies.
Table 3. (Continued)
Study Aspirin/none Mortality Deaths
(aspirin, no
aspirin)
Results
(95% CI)
Comment
Gryll et al [50] 504/3165 Cause-speciﬁc 504, N.A. HR 0.94
(0.78, 1.14)
Jacobs Chun
et al [51]
41/74 All-cause 6, 8 HR 0.44
(0.15–1.28)
High risk patients selected
Jacobs, Newton
et al [52]
301/7118 Cause speciﬁc 134, 112 HR 0.98
(0.74, 1.29)
In high risk patients: HR 0.60 (0.37, 0.97)
Stock et al [53] 453/1,619 Cause speciﬁc 115, 338 HR 1.03
(0.79, 1.34)
Survival after 5yrs of NSAIDs: HR 0.54 (0.26, 1.13)
Prostate speciﬁc mortality: HR 0.94 (0.76, 1.17), heterogeneity p<0.0005
With Assayag omitted b: HR 0.89 (0.79, 0.99) heterogeneity p = 0.261
All-cause mortality: HR 0.89 (0.30, 2.61), heterogeneity p = 0.04, Only two studies
Other cancers
Nagle et al [54] N.A. (Ovarian) Overall survival 115,338 HR 0.92
(0.81. 1.06)
Aspirin plus NSAIDs
Fontaine et al
[55]
412/1,765 (Lung) Survival N.A. HR 0.84
Pastore et al
[56]
574 (Bladder) Recurrence 42,98 OR 0.75
(0.45, 1.24)
Effect of aspirin negated by statins
Chae et al [57] 536 (Mix of female
cancers)
Survival N.A. HR 0.82
(0.57, 1.18)
PIK mutation: HR 0.59 (0.35, 0.98).Wild type: HR 1.80
(1.01, 3.23)
Chae et al [58] 280 (chronic
lymphocytic
leukaemia)
Survival N.A. HR 0.40
(0.21, 0.79).
Aspirin + statins together
MacFarlane
et al [59]
416/779 (head &
neck)
Survival 178/331 all-
cause deaths
HR 0.56
(0.44, 0.71)
Post-diagnostic aspirin
387/810
(Oesophagus)
Survival 209/756 all-
cause deaths
HR 0.54
(0.45. 0.64)
CI: conﬁdence interval; HR: hazard Ratio; N.A.: not available; NSAID: non-steroidal anti-inﬂammatory drug; OR: odds ratio; RCT: randomised controlled
trial; RR: risk ratio.
aThe inclusion of NSAIDs other than aspirin posed difﬁculties but we assumed that aspirin was the major drug used, and evidence for this is given in one
of the studies [36].
bThe examination of heterogeneity by the omission of papers was based on sensitivity analyses. The Newcastle-Ottawa grade of Frazer et al [38] and
Assayaq et al [44] were both 9/10 and correspondence with the authors revealed no likely reason the heterogeneity. The data for Bains et al (Grade 7/10)
is taken from a poster presentation and details of adjustments for confounding appear to be limited. Attempts to correspond with the author failed.
cReimers [30] reported a risk ratio and could not be included in the meta-analysis.
doi:10.1371/journal.pone.0152402.t003
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Fig 2. Forest plots of the cause specific mortality summarised in Table 3.
doi:10.1371/journal.pone.0152402.g002
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Fig 3. Forest plots of the all-causemortality summarised in Table 3.
doi:10.1371/journal.pone.0152402.g003
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Aspirin and mutations
Amutation in PIK3CA, a gene which produces a protein that increases Cox-2 and prostaglan-
din activity, has been shown to enhance the response of the tumour to aspirin. The prevalence
of this mutation is stated in several of the present studies as around 15–20% [24,27,61]. Table 5
summarises the relevant data and confirms a marked reduction in mortality in tumours with
the mutation (HR 0.45; 95% CI 0.28, 0.71), while it is uncertain if there is benefit from aspirin
in patients without the mutation (HR 0.94; 95% CI 0.67, 1.32). This last statement is based on
Table 4. Aspirin andmetastatic spread in observational studies.
Study Cohort Numbers (aspirin, no
aspirin)
Cancer Reduction
(95% CI)
Comment
Algra &
Rothwell [4]
150 Case-control and 45
cohort studies
141577 in case-control
41575 in cohorts
All
cancers
RR 0.71 (0.60,
0.84)
No reduction in localised spread: OR 0.98 (0.88–
1.09)
Choe et al [46] Selected patients from a
cancer centre
2175, 3780 Prostate RR 0.50 (0.37–
0.68)
Jacobs, Chun
et al [51]
Series of patients 45, 29 Prostate RR 0.42 (0.12,
1.45)
Reported as 12.2% vs. 26.7%, P = 0.039 at 5
years
Barron et al
[62]
Ireland National Cancer
Register
740, 2056 Breast RR 0.89 (0.81.
0.97)
Spread to lymph nodes: RR 0.81 (0.68, 0.96) in
quarter women with highest aspirin dose
Ljung et al [60] Nationwide Swedish
cohort
N.A. Breast RR 0.94 (0.87–
1.03)
Anticoagulants; 96% were aspirin
RR 0.80, (0.50–
1.29)
In younger women
HR 0.84 (0.64,
1.11)
Reduced spread to lymph nodes
RR 0.77 (0.65–0.92), heterogeneity p<0.0005, Algra 2012 [4] omitted
CI: conﬁdence interval; HR: hazard Ratio; N.A.: not available; OR: odds ratio; RR: risk ratio.
doi:10.1371/journal.pone.0152402.t004
Table 5. Effect of aspirin: relevance of PIK3CAmutation.
Authors Cancer Wild (95% CI) Mutation/overexposure (95% CI)
Cause speciﬁc mortality
Chan et al [8] Colorectal HR 1.22 (0.36, 4.18) HR 0.39 (0.20, 0.76)
Domingo et al [24] Colorectal HR 0.94 (0.59, 1.49) HR 0.11 (0.01, 0.83)
Liao et al [27] Colorectal HR 0.90 (0.53, 1.54) HR 0.28 (0.04, 2.10)
Kothari et al [61] Colorectal No patients HR 0.66 (0.31, 1,38)
‘wild’ cancers: HR 0.94 (0.67–1.32), heterogeneity P = 0.91
‘mutant’ cancers, HR 0.45 (0.28–0.71), heterogeneity P = 0.40
All-cause mortality
Chan et al [8] Colorectal HR 1.05 (0.55, 2.02) HR 0.62 (0.42, 0.93)
Domingo et al [24] Colorectal HR 0.95 (0.56, 1.61) HR 0.29 (0.04, 2.33)
Liao et al [27] Colorectal HR 0.97 (0.68, 1.37) HR 0.59 (0.24, 1.41)
Kothari et al [61] Colorectal No patients HR 0.95 (0.55, 1.63)
Chae et al [57] Several cancers HR 1.80 (1.01, 3.23) HR 0.75 (0.17, 3.20)
‘wild’ cancers: HR 1.10 (0.84–1.44), heterogeneity P = 0.31
‘mutant’ cancers, HR 0.69 (0.52–0.93), heterogeneity P = 0.66
CI: conﬁdence interval; HR: hazard ratio.
doi:10.1371/journal.pone.0152402.t005
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comparison between pairs of HRs using the normal approximation of the difference between
log HRs.
Evidence on these or other mutations appears not to be available in the present studies of
breast or prostate cancers.
Aspirin taken before a cancer diagnosis
Does aspirin treatment affect cancers which have developed while aspirin has been taken? It
may be that cancers which develop while aspirin is being taken are less responsive to the effect
of aspirin. Table 6 summarises relevant data and shows that aspirin taken before the diagnosis
of cancer is of little or no relevance to the treatment effect.
Advanced disease and high risk groups
Data in three reports of prostate cancer suggest that the effect of aspirin may be greater in
advanced disease. Thus Daugherty et al [47] describe an effect of aspirin in ‘advanced’ prostate
cancer (HR 0.37; 95% CI 0.15, 0.92) which is greater, than in localized disease (HR 0.86; 95%
CI 0.47, 1.58) Similarly Jacobs, Newton et al [52] report an HR of 0.60 (95% CI 0.37, 0.97) in
‘high-risk’ patients, contrasted with the effect of aspirin in the total cohort (HR 0.98; 95% CI
0.74, 1.29) in the total series of patients. Neither of these differences are however significant,
nor is a result reported by Jacobs, Chun et al [51] who selected ‘high risk’ patients and reported
a reduction by aspirin HR 0.44; (95% CI 0.15, 1.28).
Table 6. Aspirin also taken prior to diagnosis.
Author Cancer Aspirin only after diagnosis, not before (95% CI) Aspirin after and before diagnosis (95% CI)
Cause speciﬁc mortality
Chan et al [8] Colorectal HR 0.53 (0.33, 0.86) HR 0.89 (0.59, 1.35)
Coghill et al [22] Colorectal HR 0.77 (0.58, 1.00) HR 0.75 (0.56, 1.00)
Goh et al [36] Colorectal HR 0.81 (0.51, 1.28) HR 1.06 (0.71, 1.58)
Cardwell et al [21] Colorectal HR 1.08 (0.71, 1.63) HR 0.75 (0.43, 1.29)
Liao et al [27] Colorectal HR 0.83 (0.50–1.39) HR 0.79 (0.49–1.27)
Barron et al [62] Breast HR 0.99 (0.68, 1.46) HR 0.80 (0.62, 1.04)
Kwan et al [41] Breast RR 1.23 (0.72, 2.11) RR 0.99 (0.60, 1.64)
Assayag et al [44] Prostate HR 1.84 (1.59, 2.12) HR 0.97 (0.81. 1.16)
Jacobs/Newton et al [52] Prostate HR 0.97 (0.65, 1.45) HR 1.04 (0.73, 1.47)
Aspirin before & after diagnosis: HR 0.84 (0.70–1.00). Heterogeneity: p = 0.70 (colorectal cancer studies only)
Aspirin only after diagnosis: HR 0.79 (0.65–0.97). Heterogeneity: p = 0.30 (colorectal cancer studies only)
All-cause mortality
Bastiaannet et al [19] Colorectal HR 0.70 (0.57, 0.88) HR 0.88 (0.83, 0.94)
Chan et al [8] Colorectal HR 0.68 (0.51, 0.92) HR 0.96 (0.71, 1.28)
Walker et al [32] Colorectal HR 0.99 (0.84, 1.16) HR 0.86 (0.76, 0.98)
Goh et al [26] Colorectal HR 0.86 (0.58, 1.27) HR 1.04 (0.72, 1.48)
Liao et al [27] Colorectal HR 0.91 (0.66–1.26) HR 0.81 (0.58–1.12)
Barron et al [62] Breast HR 1.11 (0.83, 1.50) HR 0.81 (0.66, 0.99)
Assayag et al [44] Prostate HR 1.69 (1.53, 1.88) HR 0.99 (0.87, 1.18)
Macfarlane et al [59] Oesophagus HR 0.84 (0.97, 1.26) HR 1.11(0.97, 1.26)
Aspirin before and after diagnosis: HR 0.88 (0.83–0.93). Heterogeneity: p = 0.82 (colorectal cancer studies only)
Aspirin only after diagnosis: HR 0.83 (0.69–0.98) Heterogeneity: p = 0.06 (colorectal cancer studies only)
CI: conﬁdence interval; HR: hazard ratio.
doi:10.1371/journal.pone.0152402.t006
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The dose and consistency of aspirin taking
Many of the reports state, or imply that aspirin at a dose appropriate for vascular protection
had been used and only a very few reports comment further. Several studies report greater
effects with ‘high’ dose aspirin [49,63] though no difference is significant.
Several authors refer to the consistency of aspirin taking. Chan et al [8] give evidence consis-
tent with a gradient (P< 0.04), the maximum benefit being with more than five aspirin tablets
per week. Baastinnet et al [19] reported that the benefit of aspirin in all who took the drug as
HR 0.77 (95% CI 0.63, 0.95), whereas ‘frequent’ use was associated with a possible slight
increase in protection (HR 0.70; 95% CI 0.57. 0.88). Ng et al [29] reported HR 0.51 (95% CI
0.28, 0.95) for consistent use, compared with HR 0.68 (95% CI 0.42, 1.11) in the total cohort.
Fuchs et al [25] state that compared with non-consistent use, ‘consistent’ users had a much
greater reduction (HR 0.45; 95% CI 0.21, 0.97).
Several authors state that an effect of aspirin because apparent only after 3–5 years of ther-
apy. Goh et al [26] state that they found evidence of benefit only after 5 years, Stock et al [53]
who reported no benefit to prostate cancer overall (HR 1.03; 95% CI 0.79, 1.34) states that after
five years of aspirin taking there was benefit (HR 0.54; 95% CI 0.26, 1.13) and an effect of aspi-
rin taking in the study of lung cancer [55] became significant only after three years (HR = 0.84;
CIs not stated).
Aspirin and bleeding
An excess of bleeding attributable to aspirin has been well studied in short-term vascular trials
[64,65]. It is however appropriate to ask whether or not the risk of bleeding attributable to aspi-
rin is similar in patients with cancer to that reported from the vascular trials. A few reports in
the present series give a measure of reassurance on this. Din et al [23] who examined NSAID
use state that there were no major bleeding complications. Liu et al [18] state that no side
effects caused by aspirin were noted in any patient in the study. Curigliano et al [66] examined
short-term aspirin taking by patients with breast cancer and stated that no major bleeding
complication occurred.
The corresponding authors of the other reports in this series were written to. Replies
received from twenty-one authors stated that no data on bleeding had been recorded.
Discussion
The evidence we present from a systematic overview of the literature gives support to the use of
aspirin as an additional treatment of cancer. The evidence is limited, and while it is encourag-
ing in the case of bowel cancer, there is insufficient evidence to dismiss a role for aspirin as an
adjunct treatment of cancers other than colorectal. In fact, its use can be justified on the basis
of its likely benefit on outcomes other than death, including its probable reduction in meta-
static spread and its reduction in vascular disease events, including venous thromboembolism.
Differences between individual studies leading to significant heterogeneity is to be expected
in any collection of observational studies such as those we present, and it does limit confidence
in the results. However, if, for each of the three cancers, an out-lying study identified by
detailed sensitivity analyses is omitted, heterogeneity is reduced to an acceptable level and for
each cancer there is evidence suggestive of reductions in mortality and in metastatic spread.
In colon cancer there is evidence of a reduction in colorectal deaths of about 25%, and per-
haps about 20% in All-cause mortality. If one report [13] is omitted the evidence of benefit in
breast cancer is of a possible 13% reduction in cause-specific deaths, and for prostate cancer a
possible reduction of perhaps about 11%.
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With the present level of evidence, the pooling of data for the three cancers would seem to
be not unreasonable and following omissions of three outliers, unacceptable heterogeneity is
resolved. A meta-analysis then suggests a possible overall reduction by aspirin of about 15%
(pooled HR 0.83; 95% CI 0.76–0.90). The evidence of a reduction in metastatic spread (RR
0.77; 95% CI 0.65–0.92) gives further encouragement to the use of therapeutic aspirin in cancer
while awaiting evidence from ad hoc randomised trials.
It would be unreasonable to attempt to draw firm conclusions from the single studies on
lung cancer [31], on oesophageal cancer [45], and on lymphatic leukaemia [22]. However the
suggestive benefit in these studies, together with that reported for a mix of colon and women’s
cancer [21] indicates an urgent need for more observational studies in the less common can-
cers, some of which may never be subjected to evaluation in randomised trials. It would also be
helpful if in the reporting of new studies information on the stage and grade etc. of the cancers
could be indicated.
The evidence we present on the biomarker PIK3CA has been confirmed in an overviews by
other authors [67], and similar data on other markers have been shown by other authors [68].
Thus Sun et al [31] who examined CTNNB1, a gene associated with cell adhesion and of rele-
vant to familial polyposis, reported a marked enhancement in the effect of aspirin (HR 0,53;
95% CI 0.30, 0.95) compared with the effect in patients with the wild gene (HR 1.06; 95% CI
0.62, 1.83). A different approach to this issue was adopted by Chan et al [8] who used an over-
expression of COX-2 in the primary tumour as an indication of a relevant mutation, and
showed that overexpression was associated with reductions in colon cancer mortality (HR 0.39;
95% CI 0.20, 0.76) compared with the effect in other patients (HR 1.22; 95% CI 0.36, 4.18).
All this suggests that the reduction by aspirin may be restricted to patients whose tumours
show mutation in PIK3CA, HLA class I antigen, or show COX-2 over-expression. In colorectal
cancer these subgroups represent approximately 17%, 54% and 50% of all patients, and our
data suggest a reduction of about 50% in colorectal mortality, though another overview [67]
suggested a reduction of only about 30%, while neither overview showed any reduction in
those without the mutation. The scarcity of evidence on mutation in cancers other than colon
is most unfortunate [69].
And yet any selection of patients for treatment with aspirin on the basis of a mutation or
any other marker of cancer risk would be totally unwarranted on present evidence. Metastases
are a major source of pain and other undesirable effects in solid cancers [70,71] and perhaps
90% of cancer deaths are at least in part due to metastases [72] and the withholding of aspirin
would deny these possible benefits. Furthermore, the risk factors for vascular disease overlap
with those for cancer and the withholding of aspirin would also deny patients the vascular ben-
efits of aspirin, including the possible reduction of the excess risk of venous thromboembolism
during chemotherapy. In fact, the marked increase in the risk of venous thrombosis in patients
with cancer [66,73], has been shown to be reduced by low-dose aspirin [74], and it has there-
fore been recommended that prophylactic anticoagulants should be considered in all patients
with cancer [75].
A major uncertainty in what we report arises from the possible omission of relevant reports,
together with publication bias, and the test we performed suggests that this last may have
occurred (Egger's test [13] P = 0.037). Furthermore, underlying all observational studies is the
issue of residual confounding, and while this cannot be dismissed, it seems unlikely to have
operated to any important degree as all the studies reviewed included multivariate
adjustments.
On the other hand certain time biases could be present in some of the studies, and especially
in retrospective case-control studies [76]. Patients not taking aspirin at the time of diagnosis
can be defined, used as ‘controls’ and followed thereafter. Patients who start taking aspirin
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after receiving a diagnosis of cancer cannot be identified as ‘cases’ until they start taking the
drug. It is possible that these will be identified later than the ‘control’ patients, and they will
therefore be observed and deaths identified during a shorter time that that during which the
patients not taking aspirin are observed. This has been called an ‘immortal’ time bias and
Assayag & Azolay [44] include a detailed discussion of it.
All the reports in the present series were examined and while immortal time bias cannot be
dismissed with certainty, an important effect upon the overall estimates of the effect of aspirin
seems most unlikely. In fact, there is little difference in the overall mortality of the patients who
had taken aspirin before diagnosis, and (presumably) continued to take it after diagnosis (HR
0.92), and the patients who had not taken aspirin before diagnosis (HR 0.90), in whom there
could have been a time lag and thus, an ‘immortal time bias’ (see Table 6).
While a serious limitation in the present evidence is that little comes from randomised trials,
yet evidence from further observational studies is urgently needed to evaluate more fully how
patients likely to benefit from aspirin can be identified. In particular evidence on PIK3CA, other
mutations and other possible markers should be collected as a matter of urgency in cancers of
breast, prostate and other organs. The results of such studies should be made available for the
encouragement and guidance of colleagues setting up randomised trials, and, in fact, the further
question arises whether or not these mutations are of relevance to aspirin used in prophylaxis.
The possible benefits of aspirin must of course be evaluated against it side effects. Shortly
after aspirin taking commences the risk of a gastrointestinal (GI) bleed is high but the risk falls
rapidly thereafter [77,78], and in short-term trials the additional risk of a bleed from low-dose
aspirin amounts to perhaps one or perhaps two patients in every 1,000 on low-dose aspirin
[64,65]. After about three years of aspirin taking however, there appears to be no evidence of
any excess GI bleeds attributable to the drug [78]. Moreover, the incidence of GI bleeding is
highly sensitive to the presence of gastric pathology [78,79], and careful enquiries should there-
fore be made about current or past gastric symptoms, and about a high alcohol consumption
[80]. The use of a gastroprotective drug together with the aspirin should be carefully considered
if pathology is suspected.
The most serious bleeds are those that lead to death, and despite frequent references to fatal
bleeds attributed to aspirin, there appears to be no valid evidence that deaths from GI bleeds are
increased by low-dose aspirin [81]. In a recent study of patients admitted to hospital with ‘gross’
GI bleeding [82] the hospital stay of patients who had been taking aspirin was significantly
shorter than that of patients who had not been on aspirin, and no patient whose bleed had been
attributed to aspirin experienced an uncontrolled haemorrhage or died due to excessive bleeding.
Cerebral bleeds attributable to aspirin are rare, about one or two per 10,000 patient-years.
Hypertension is the major factor in such bleeds [2] and in a randomised trial of aspirin based
upon patients with hypertensive disease all of whom were adequately treated with anti-hyper-
tensive drugs, there was the same number of cerebral bleeds in ten thousand patients on aspirin
(19 patients) as in ten thousand on placebo (20 patients) [83]. A reduction in the risk of a cere-
bral bleed is therefore likely if the blood pressure of every person starting aspirin is checked,
and adequately treated if raised [84].
Other overviews
An early overview of studies of aspirin and cancer was based on three small randomised trials
and two observational trials, and this led to the conclusion: ‘aspirin may have a role in the adju-
vant setting. . . and should not be overlooked [9]. A further overview of three studies of colorec-
tal, one of breast, two of prostate and one of oesophageal cancers judged that aspirin decreases
the development and spread of metastases [10].
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Li et al [85] reported a systematic review and meta-analysis of seven studies of colorectal
cancer. Aspirin use after a diagnosis of colon cancer was reported to reduce overall all-cause
mortality (HR 0.84; 95% CI 0.75, 0.94), but if aspirin had been taken before cancer benefit was
uncertain (HR 0.77; 95% CI 0.52, 1.14). Ye et al [86] conducted a meta-analysis of seven of the
studies of colon cancer in the present review, and reported effects of aspirin on both colon can-
cer mortality and overall mortality very close to what we report.
Huang et al [87] identified 16 studies in which a NSAID or aspirin had been used in patients
with breast cancer. On the basis of meta-analyses they reported that aspirin taken after diagno-
sis, but not before, was associated with improved breast cancer survival (HR 0.69; 95% CI 0.50,
0.96). Zong et al [88] also reported a systematic review and meta-analysis of breast cancer
patients in eight cohort studies and two nested case-control studies, and judged that post-diag-
nostic aspirin was associated with a significant reduction in the relative risk of death from
breast cancer (RR 0.84; 95% CI 0.63, 1.12). Liu et al [89] conducted a systematic review and
identified 39 studies of NSAIDs, including aspirin. A meta-analysis of prostate specific mortal-
ity in seven studies of aspirin gave an HR = 0.86 (95% CI 0.78, 0.96) and the effect of aspirin in
these studies were judged to be more consistent than those for other NSAIDs.
Conclusions
It appears likely that low-dose aspirin has a beneficial role as an adjunct treatment of cancer.
Reductions in mortality are shown in colon cancer, probably in prostate cancer and possibly in
breast and individual studies of several other cancers also suggest benefit. Aspirin benefit in
colorectal cancers, and possible other cancers, may be restricted to patients with tumours
expressing certain genetic mutations. However, other benefits of low-dose aspirin, including
reductions in metastatic spread and in vascular events, including venous thromboembolism
appear to be independent of these biomarkers, and so information on aspirin should be given
to patients whatever the state of the possible biomarkers.
The heterogeneity within the currently available studies–both between different cancers,
and within the different studies of each cancer, together with evidence suggesting some publi-
cation bias, are such that further evidence from a number of adequately powered randomised,
placebo controlled trials is urgently required, including trials of less common cancers. Evidence
on the possible role of aspirin in uncommon cancers, and the possible enhancement of its effect
if mutation and other markers of increased sensitivity to the actions of aspirin, are also urgently
needed. Much of this evidence could some from further observational studies.
Nevertheless, despite the need for randomised trials, we believe the evidence of benefit from
aspirin is sufficiently persuasive that physicians should engage with patients in a presentation
and discussion of aspirin as an additional treatment. Furthermore, we hold that patients should
be given this evidence within the context of a healthy lifestyle [90], they should be allowed to
make their own decision about aspirin therapy, and should then be supported in whatever deci-
sion they make [91].
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